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Synopsis: 
Radionuclide treatment has been shown to be quite effective in the management of 
advanced paragangliomas and pheochromocytomas. Apart from I(131)-MIBG which has 
been used in the past, recently, peptide receptor radionuclide treatment (PRRT) has been 
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shown to be effective in the management of these tumors. We present series of patients 
showing their response to these treatments. 
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Abstract  
 
Background and objectives: Radionuclide therapy has been used to treat patients with 
progressive/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs).  The 
aim of the present study is to retrospectively compare the therapeutic outcomes of these 
modalities in patients with progressive/metastatic PCCs and PGLs. 
Methods: Patients with progressive/metastatic PGLs and PCCs that were subjected to 
radionuclide treatment in our department were retrieved from our department’s database 
for the period 1998-2013. Overall survival (OS), progression free survival (PFS), event 
free survival (EFS) and response to treatment were calculated. Treatment toxicity was 
documented.  
Results: Twenty two patients with progressive/metastatic PGLs or PCCs were treated 
with either (131)I-MIBG, (90)Y-DOTATATE or (177)Lu-DOTATATE. A total of 30 
treatments were administered (16 treatments with (131)I-MIBG, 2 with (177)Lu-
DOTATATE and 12 with (90)Y-DOTATATE. Patients treated with PRRT had increased 
PFS and response to treatment compared to (131)I-MIBG treated patients (p<0.05). 
However, difference in OS was non significant (p=0.09). There was no difference in 
major toxicities between groups. When comparing only patients with PGLs, OS, PFS, 
EFS and response to treatment were significantly higher in the PRRT treatment group.  
Conclusion: PRRT treatment offers increased OS, PFS, EFS and response to treatment 
compared to (131)I-MIBG therapy in patients with progressive/malignant PGLs. 
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Introduction  
Phaeochromocytomas (PCC) and paragangliomas (PGL) are tumors of chromaffin cells 
that often produce and secrete catecholamines and their metabolites. PCC occur within 
the adrenal medulla and PGL present as  tumors of the extra-adrenal sympathetic nervous 
system, occurring in the head and neck, chest, abdomen, or pelvis [1]. These tumors can 
present either as benign, in the majority of the cases, or may be malignant.  
There are currently no established criteria for establishing PCC/PGL as malignant apart 
from the presence of metastases at diagnosis [2]. In cases where metastases are found, 
surgery is usually of limited therapeutic value and other therapeutic modalities have been 
proposed. These include chemotherapy, external radiotherapy, radiofrequency ablation 
therapy, tyrosine kinase receptor inhibitors and radionuclide therapy [2-6].  
(131)I-metaiodobenzylguanidine (MIBG) is a frequently used treatment for advanced 
neuroendocrine tumors, leading to symptomatic control, stabilization of disease 
progression and increased overall survival [7]. Peptide Receptor Radionuclide treatment 
(PRRT) with radiolabeled somatostatin analogues have also been used in the treatment of 
neuroendocrine tumors. However, data on PRRT use in metastatic PCCs and PGLs are 
limited. There are a few reports for the treatment of these patients with PRRT, and 
although this therapy seems effective, it is not reported to be as effective as in other 
subtypes of neuroendocrine tumors [8-10]. 
To date, there is no study comparing (131)I-MIBG treatment and PRRT in the 
management of patients with progressive PCCs and PGLs. The aim of the present study 
is to retrospectively compare MIBG and PRRT treatment in patients with 
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metastatic/progressive PCCs and PGLs, in terms of overall survival, progression free 
survival, event free survival, response to treatment, and toxicity.  
 
 
 Materials and Methods 
 
Population 
This was a retrospective study of the patients with locally advanced /metastatic 
progressive PGLs and PCCs treated in our department during the period 1998-2013. All 
patients were characterized as “metastatic” either during follow-up after initial surgery, or 
when metastases were present at tumor diagnosis.  
The decision for commencement of radionuclide therapy was made in the Neuroendorine 
Tumour Multi-Disciplinary Team meeting and was based on either disease progression 
and/or failure to control symptoms of catecholamine hypersecretion. Patients were 
allocated to either (131)I-MIBG or PRRT treatment, according to their respective tumor 
avidities for (123)I-MIBG versus somatostatin receptor agonist tracers, either (111)In- 
diethylenetriaminepentaacetic acid (DTPA)-Octreotide or (68)Ga- tetraazacyclododecane 
tetraacetic acid octreotate (DOTATATE). Patients that had metastatic 
pheaochromocytomas were scanned for (123)I- MIBG avidity and then scanned for  
somatostatin analogue peptide avidity if there was no avidity or poor avidity to (123)I- 
MIBG. Patients with metastatic paragangliomas were checked for avidity to (123)I- 
MIBG and when negative for avidity to somatostatin receptor agonist tracers. In view of 
this patients in our series were not routinely scanned for both modalities throughout the 
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entire study period. However, during the years of the study period imaging with 
somatostatin receptor agonist tracers has increased in our department as a result of the 
increased avidity that has been shown in patients with PGLs.  
Patients with non-progressive and symptomatically controlled disease, surgically 
treatable primary or metastatic disease, as well as patients with renal failure or bone 
marrow disease were excluded from radionuclide treatment. 
Patient age, sex, tumor type, tumor location, genetic background, the presence of 
metastasis on diagnosis, the operability, the extent of metastatic disease, the functionality 
of the tumor and the administration of additional therapies were recorded. 
As this was a retrospective audit of practice, research ethical approval was not required.  
 
Radionuclide Therapy Protocol 
(131)I-MIBG 
All patients had a pre-therapy (123)I-MIBG scan to assess appropriate uptake of tracer in 
the sites of known disease. The administered activity of (123)I-MIBG was 220 MBq with 
scans performed on a dual-head gamma camera using a low-energy high-resolution 
collimator 24 h after injection.  
Treatment was administered in a shielded side-room on the oncology ward. Patients 
underwent thyroid blockade with oral potassium iodide prior to treatment, starting on the 
day of the therapy and continued for a further 4 days after therapy. Ondansetron 8 mg 
orally was also given 30 min before the (131)I-MIBG to minimize nausea. Standard 
activity varied over the years. In patients treated after the year 2000, the standard activity 
administered was of 5.5 or 7.4 GBq of (131)I-MIBG (GE Healthcare, Amersham, 
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Buckinghamshire, UK) in two vials (5.5 GBq) or three vials (7.4 GBq). The standard 
protocol involved three cycles of (131)I-MIBG therapies with intervals of 10–12 weeks 
between each treatment. Fewer than three cycles were administered if there was any 
evidence of significant toxicity. Patients before 2000 were treated using two different 
regimes. Those with fast-growing tumours and significant symptoms were treated with 
three infusions of 131I-MIBG, given at 10- week to 12-week intervals. If there was 
evidence of response, the patients were then maintained on 6- monthly treatments. In 
those patients with m re slowly growing disease, 6-monthly treatments were used from 
the outset. 
Treatment was administered over approximately 40 min using a semi-automated delivery 
system (GE Healthcare, Amersham, Buckinghamshire, UK), with 90% of activity passing 
from the delivery system to the patient. Cardiovascular monitoring was routinely used 
during administration. Patients were closely observed from behind a lead shield during 
the administration. Patients were monitored by the hospital radiation safety group and 
discharged when their dose rate at 1 m had fallen to ≤600 MBq. Two to three days after 
treatment, a post-therapy whole-body scan was obtained on a dual-head gamma camera 
using a high energy general purpose collimator. This was performed to assess the 
biodistribution of the tracer. 
PRRT 
Treatment was administered in a shielded side-room on the oncology ward. Ondansetron 
8 mg was injected intravenously and an infusion of amino acids containing lysine 25g 
and arginine 25g in 2 L 0.9% NaCl was started 30 minutes before the administration of 
the radiopharmaceutical and lasted 4 hours. The radiopharmaceutical [either (90)Y-
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DOTATATE or (177)Lu-DOTATATE] was co-administered via a second pump system. 
Cycle activities given were 3.2 GBq for Y-90 DOTATATE and 7.4 GBq for Lu-177 
DOTATATE, injected over 30 minutes. The standard protocol involved three to four 
cycles of therapies with intervals of 10–12 weeks between each treatment. Fewer cycles 
were administered if there was any evidence of significant toxicity. 
 
Follow-Up 
Patients’ symptoms and adverse effects were evaluated after each cycle and overall 3 
months following the completion of treatment courses.  Routine haematology, liver, 
renal, and thyroid function tests, as well as tumour markers were performed before each 
therapy, as well as at follow-up visits. Follow up was discontinued only if the patient died 
or were assigned to palliative care, when only information concerning the patients’ status 
were recorded. 
Although biochemical and symptomatic response was evaluated with blood 
investigations and quality of life questionnaires (EORTC QLQ – GI.NET21), this was not 
done consistently and per protocol and as a result data were not eligible for retrospective 
collection and analysis. 
Patients underwent restaging cross-sectional imaging (CT or MRI) between 6 weeks and 
3 months after the completion of treatment courses and then every 4-6 months. Tumor 
response to treatment was evaluated retrospectively according to the RECIST 1.1 criteria. 
All imaging were reviewed by an experienced radiologist.  
Progression free survival was defined as the interval between the first radionuclide 
treatment and the radiological progression of the disease, or death related to the disease. 
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Time to progression was also calculated and was defined as interval between the first 
radionuclide treatment and the radiological progression of the disease without taking 
death into account. Finally, as we did not have any consistent data on quality of life after 
the treatment, we calculated event free survival, which was defined as the interval 
between the first radionuclide treatment and any event related to radiological progression, 
major toxicity, any major disease related event that lead to hospitalization or death. As 
many patients were subjected to multiple treatments, progression free survival, time to 
progression, event free survival and response to treatment were calculated individually 
for every treatment and not per patient. Overall survival was calculated for every patient 
and was defined as the interval between the first radionuclide treatment and death.  
 
Treatment toxicity 
Minor side effects, during or after treatments, were not recorded. Data for major side 
effects of treatment, in terms of haematological and renal toxicity, were collected. Renal 
and haematological toxicity were graded, according to the National Cancer Institute 
Toxicity Criteria. 
 
Statistical Analysis 
Results are expressed as mean ± standard deviation (SD). Comparison between groups 
was performed using the Chi-Square test for qualitative data and the unpaired t-test for 
quantitative data. Overall Kaplan–Meier survival curves, progression-free Kaplan–Meier 
survival curves, time to progression curves and event free survival curves were generated 
for each group and compared with a log-rank test for proportional hazards and the 
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Breslow test if differences were depicted early in the follow up period. A p value smaller 
than 0.05 was considered as significant. 
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Results 
During the period 1998-2013 we found 22 patients with progressive metastatic 
paragangliomas or phaeochromocytomas that were referred for radionuclide therapy with 
either (131)I-MIBG, (90)Y-DOTATATE and (177)Lu-DOTATATE.  The mean age at 
diagnosis was 46.9 ± 15 years. Patient characteristics are summarized in TABLE 1.  
From the 22 patients receiving radionuclide treatment 8 patients received treatment with 
(90)Y-DOTATATE, 1 patient treatment with (177)Lu-DOTATATE, 11 patients 
treatment with (131)I-MIBG and 2 patients received a combination of the above 
treatments. A total of 30 treatments were administered in these patients. Analytically, 
these consisted of 16 treatments with (131)I-MIBG, 2 treatments with (177)Lu-
DOTATATE and 12 treatment cycles of (90)Y-DOTATATE. The seven patients with 
PCCs were subjected to 9 treatments, 8 of which were with (131)I-MIBG and one with 
(90)Y-DOTATATE. The 15 with PGLs were subjected to 21 treatments, from which 13 
were with PRRT and 8 were with (131)I-MIBG. The above data, cumulative dosage, 
treatment cycles and total number of treatments are summarized in TABLE 2. 
Patients were followed up continuously in our departments’ outpatient clinic. The follow-
up period ranged from 6 to 122 months (mean 38.7 months) for patients that eventually 
died and 2 to 134 months (mean 56.4 months) for patients that were alive at the end of  
the study period. We had no patients lost in follow-up. Overall survival was compared 
between patients that received (131)I-MIBG or PRRT treatment, and thereafter between 
patients treated with (131)I-MIBG and (90)Y-DOTATATE. Only two patients received 
(177)Lu-DOTATATE, thus making the addition of an additional group not applicable. 
Overall survival was not different when comparing treatments with (131)I-MIBG versus 
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PRRT, or (131)I-MIBG versus (90)Y-DOTATATE (p=0.09 and p=0.08 respectively). 
Further stratification of the two treatment groups according to tumor type was made. All 
patients with progressive/metastatic PCCs were treated with (131)I-MIBG or a 
combination of (131)I-MIBG with PRRT (as per imaging avidity protocol) and as a result 
no comparison was made. Patients with progressive/metastatic PGLs had a longer overall 
survival when treated with PRRT or (90)Y-DOTATATE compared to (131)I-MIBG 
(p=0.01).  
Progression free survival for all patients was longer in patients treated with (90)Y-
DOTATATE compared with (131)I-MIBG (p=0.04), however, this difference was not 
statistically significant when comparing all PRRT treated patients (p=0.1). In patients 
with PGLs, progression free survival was longer after PRRT or (90)Y-DOTATATE 
treatment compared to patients treated with (131)I-MIBG (p=0.01 and p= 0.007, 
respectively). There were no differences in time to progression or event free survival 
between these treatment groups, when including all patients. However, in patients with 
PGLs, event free survival was longer both after (90)Y-DOTATATE (p=0.02) or any 
PRRT treatment (p=0.04), compared with patients treated with (131)I-MIBG. Data are 
summarized in TABLES 3 and 4 and FIGURE 1 and 2.  
Response to treatment, as determined by RECIST 1.1 criteria, was significantly better 
after PRRT, in general, and after (90)Y-DOTATATE treatment compared to (131)I-
MIBG treated patients (p= 0.013 and p=0.021 respectively). When comparing patients 
with PGLs separately, response to treatment was also higher when comparing either 
PRRT, in general, or (90)Y-DOTATATE treatment specifically with (131)I-MIBG 
treated patients (p=0.005 and p=0.008, respectively).  
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Six patients (27.2%) developed renal impairment during their follow up. However, not all 
of these toxic events were related to the radionuclide treatment. In one case renal 
impairment was due to ureteric obstruction from the tumor and in another case renal 
impairment was secondary to NSAID treatment after a metastatic fracture. When these 
cases were excluded, only 4 (18.1%) patients developed renal toxicity related to 
radionuclide treatment, of which only 2 (9%) were serious (Grade 3 or 4). One of the 
patients was treated with PRRT, while the other one was treated with a combination of 
(131)I-MIBG and PRRT. Nine (40.9%) patients had haematological complications during 
their follow up, but only 5 cases (22.7%) could be attributed to radionuclide treatment. 
There was no difference in haematological toxicity between patients treated with (131)I-
MIBG and patients treated with (90)Y-DOTATATE therapy. Both renal and 
haematological side effects are summarized in Table 5.  
 
 
Discussion  
The management of patients with metastatic PCCs and PGLs can be challenging. 
Although multiple therapeutic modalities exist, including chemotherapy, external beam 
radiation, tyrosine kinase inhibitors and surgery in some cases, radionuclide treatment has 
been shown to be most effective in the treatment of those patients [10-12]. Traditionally, 
(131)I-MIBG has been shown to have a high tracer affinity for these tumors [13]. During 
the last decades, radionuclide imaging with radiolabeled somatostatin analogues has been 
shown to be an alternative option, as well, leading to respective therapeutic interventions 
[8]. (90)Y-(DOTATOC), (90)Y-DOTATATE and (177)Lu-DOTATATE are the main 
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peptide receptor radionuclide treatment used to date [8-10,14]. The literature is scarce in 
studies comparing these two agents in neuroendocrine tumors in general, while there is 
no study to date comparing these treatment modalities in metastatic/progressive 
PCCs/PGLs.  
In our study, most of the PRRT treatments used (90)Y-DOTATATE, with the exception 
of two patients that received (177)Lu-DOTATATE (one as a monotherapy and one as an 
additional treatment cycle after previous (131)I-MIBG treatment). This was due to the 
fact that (177)Lu-DOTATATE was not available in our department during the entire data 
collection period, and became available after 2011.  
Patients with metastatic PCCs were treated mainly with (131)I-MIBG. On the contrary, 
patients with metastatic PGLs were treated either with (131)I-MIBG or PRRT, mostly 
with (90)Y-DOTATATE. This can be explained by the fact that patients with PCCs were 
mostly (123)I-MIBG avid. The opposite was true for patients with PGLs, where there 
was increased avidity for somatostatin receptor radionuclide imaging. During the last 
decades diagnostic imaging strategies have changed significantly for these two tumors. 
Traditionally these tumors were both imaged with MIBG, until a significant percentage 
of PGLs and some PCCs were found to be avid to (111)In- (DTPA)-Octreotide scan    
and even bigger percentage avid to (68)Ga- (DOTATATE) PET. In view of this the 
imaging protocol of these patients in our department has evolved as well during the study 
period. This is in accordance with the literature [15-18].  
Overall survival was not significantly different when comparing (131)I-MIBG and PRRT 
treatments in the entire study population. However, when only patients with PGLs were 
compared, there was a difference in overall survival between the treatment groups. The 
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difference in our results when stratifying for tumor type can be interpreted by a difference 
in the efficacy of the two treatment modalities. 
The two treatment modalities were also compared in PFS, TTP, EFS and response to 
treatment. Our results show that PRRT seems to be more effective than (131)I-MIBG in 
terms of response to treatment, but with no difference in PFS, TTP and EFS in patients 
with metastatic PGLs and PCCs. However, when comparing only patients treated with 
(90)Y-DOTATATE, they had increased response to treatment, as well as PFS.  
Very few studies have addressed the effect of PRRT in the management of patients with 
metastatic PGLs and PCCs. Recently, Forrer reported an overall response to treatment in 
22 of 28 (78%) patients, with a PFS ranging from 3 to 43 months [8].  Prasad et al also 
reported the results of PRRT [(90)Y-DOTATATE, (177)Lu-DOTATATE and 
combination] in 20 patients with progressive PGLs and PCCs. They reported an 80% and 
43% overall response rate with (177)Lu-(DOTATATE and (90)Y-DOTATATE 
treatment, respectively. Best results were reported after combination treatment [9]. 
Recently, Puranik et al reported a series of 9 patients with inoperable head and neck 
paragangliomas treated with PRRT. They demonstrated disease stabilization and 
symptomatic relief of these patients after treatment. However, theirs study did not 
concern metastatic disease as only one of the nine patients had distant metastasis [10].   
In our study, we have shown a response in 11 of 11 (100%) treatments with (90)Y-
DOTATATE and a mean PFS of 43 months. However, this result should be interpreted 
with caution, as one of the patients in this group had initially presented with a locally 
inoperable and symptomatic PGL, received radionuclide treatment and later developed 
metastases. In addition, in our study, response to treatment was evaluated 6 weeks to 3 
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months after treatment and according to RECIST 1.1 criteria, as opposed to WHO and 
other criteria used in other studies [7].  
Radionuclide treatment with (131)I-MIBG has been better studied in patients with 
progressive/malignant  PCCs and PGLs. Recently, Gonias et al reported a phase II 
prospective study of 50 patients with malignant disease that were treated with high dose 
(131) MIBG. In their study, they reported 27% response to treatment and 80% non-
progressive disease with radiologic criteria after the first treatment. In our study we 
observed 62.5% non- progressive disease after (131)I-MIBG treatment sessions. 
However, in their study they evaluated response rate 3 to 6 months after the treatment, in 
contrast to our study, where the response rate was evaluated 6 to 12 weeks after 
treatment. In addition, in their study, they incorporated patients receiving a higher dose 
protocol for (131)I-MIBG, compared to our study. Fitzgerald et al also reported an initial 
83 % overall response rate after high dose (131)I-MIBG treatment in patients with PGLs 
and PCCs. Some patients showed progression later in their follow up and the overall 
response rate became 66%[1].  
An interesting finding in our study is that efficacy of tr atment seems to be different 
between patients with PCCs and PGLs, suggesting that these two pathologies should 
probably not be treated similarly. PRRT was found to be of no benefit to OS, OFS, EFS 
and TTP compared to (131)I-MIBG when including all the patients in the analysis. 
However, there was a clear benefit in terms of response to treatment. One could argue 
that PCC patients were only treated with (131)I-MIBG or a combination of (131)I-MIBG 
and PRRT and these patients have been reported to have worse prognosis that patients 
with PGLs, thus effecting our results. However, we noted a clear difference in overall 
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survival, PFS, EFS and response to treatment in favor of PRRT when comparing only 
patients with metastatic PGLs, as opposed to incorporating PCCs in the comparison. A 
similar comparison could not be made for PCC patients due to the retrospective nature of 
the study, as all patients with PCCs were treated with (131)I-MIBG or a combination of 
(131)I-MIBG and PRRT. It is possible that PCCs and PGLs have a different response to 
(131)I-MIBG or PRRT. Chen et al have shown that somatostatin receptor scintigraphy is 
more sensitive than (131)I-MIBG imaging in the detection of extra-adrenal 
phaeochromocytomas using (99m)Tc-HYNIC-TOC as a tracer [15]. In the same time, 
Koopmans et al have reported similar data for the affinity of head and neck 
paragangliomas using (111)In-octreotide vs (123)I-MIBG [16]. In keeping with this, Jalil 
et al has reported a sensitivity of 88% for the detection of unilateral PCCs as opposed to 
64% for extra adrenal tumors using (131)I-MIBG scintigraphy [19]. Bhatia et al have 
published similar results (85% for PCCs and 58% for PGLs) with (123)I-MIBG 
scintigraphy.  
The single most important finding of our study was that patients with metastatic PGLs 
seem to have a better prognosis when receiving PRRT treatment instead of (131)I-MIBG. 
In view of this it seems more rational that these patients be preferentially scanned for 
somatostatin receptor agonist tracer avidity and only when no avidity is found, for  
(123)I-MIBG avidity. However, the same cannot be said for patients with metastatic 
PCCs, direct comparison between the two treatments could not be made in our study. 
A major limitation of our study includes the retrospective nature of the data collection. In 
addition, the PRRT group included only a small number of patients treated with (177)Lu-
DOTATATE, since it has only been available in our unit since 2011. In the (131)I-MIBG 
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treatment group dosage protocols varied during the period studied and as a result, there is 
heterogeneity in the treatment protocol between patients. Our unit’s protocols did not 
include high dosage treatments, which has been reported to be quite effective in 
neuroendocrine tumors in general and PGLs/PCCs in particular. Recent data have also 
speculated the role of a combination of these treatment modalities, in order to be able to 
maximize efficiency and limit toxicity, which we did not address in our study [20,21]. 
Finally, we did not have comparative data on symptomatic/biochemical response or 
quality of life after the above treatments in these patients. Prospective studies, preferably 
with stratification of cohorts for tracer avidity and utilizing (177)Lu-DOTATATE as the 
current standard of treatment for PRRT, are required to address these limitations and to 
confirm or refute our conclusions.  
 
Conclusion 
 
This is the first comparative study between radionuclide treatments for patients with 
metastatic/progressive PGLs and PCCs. These patients ar  usually studied as a group in 
most studies. Our study has shown superiority of PRRT compared to (131)I-MIBG 
treatment in these patients, with a pronounced effect when comparing PGL patients 
alone. Comparative data and results in our study seem to rely mostly on patients with 
progressive/malignant PGLs. Although the mainstream therapy for progressive/malignant 
PCCs is (131)I-MIBG, there might be a benefit from PRRT treatment as well. This 
should be addressed in future prospective trials. 
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Figure legends 
 
Figure 1 
Kaplan Meier Curves comparing Overall Survival, Progression Free Survival and Event 
Free Survival between patients with Paragangliomas and Phaeochromocytomas treated 
with a) (131)I-MIBG vs PRRT and b) (131)I-MIBG vs (90)Y-DOTATATE. 
(* p<0.05) 
 
Figure 2  
Kaplan Meier Curves comparing Overall Survival, Progression Free Survival and Event 
Free Survival only in patients with Paragangliomas treated with a) (131)I-MIBG vs 
PRRT and b) (131)I-MIBG vs (90)Y-DOTATATE. 
(* p<0.05) 
 
 
Page 22 of 30
John Wiley & Sons, Inc.
Journal of Surgical Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 1 Characteristics of patients treated with radionuclide therapy  
 
Case Age Sex Tumor 
Genetic 
Testing 
Metastatic 
at 
diagnosis 
Extent of Disease 
prior to radionuclide 
treatment 
Clinically 
Functioning 
Tumor 
Mitosis index 
1 56 M Phaeo - No Liver Yes N/A 
2 71 F Para - Yes Liver Yes 
<1%MIB-1 
staining 
3 41 M Para - No 
Lungs, Liver, Lymph 
nodes 
No 
3 mitoses per 
10hpf 
4 39 M Para SDH-B Yes Bones No N/A 
5 7 F Para - No Liver, Lymph Nodes Yes N/A 
6 56 F Para - Yes Bones Yes 
1-5% MIB-1 
staining 
7 43 M Phaeo - Yes Bones No N/A 
8 59 M Phaeo - No Liver, Bone Yes N/A 
9 51 F Phaeo - Yes N/A No N/A 
10 63 M Phaeo - No Lung, Lymph nodes Yes 
10% Ki-67 
staining 
11 49 F Para SDH-B Yes 
Liver, Bone, Lymph 
Nodes 
Yes N/A 
12 29 M Para - No 
Lungs, Bone, Liver, 
Lymph Nodes 
Yes N/A 
13 65 M Para - No Bones No 
15-20% 
staining 
14 57 M Para - Yes Bones, Lymph nodes No 
30% Ki-67 
staining 
15 44 F Para - No Bones Yes N/A 
16 40 M Para SDH-B Yes Bones, Liver Yes 
50% Ki-67 
staining 
17 42 F Para - No *, Bones No 
1% MIB-1 
staining 
18 35 M Para SDH-B Yes 
Lymph nodes, Soft 
tissue 
Yes N/A 
19 68 F Phaeo - No 
Lung, Liver, Lymph 
nodes 
No 
10% MIB-1 
staining 
20 29 F Para SDH-B Yes Liver, Lymph nodes No 
5-10% MIB-1 
staining 
21 36 F Para - No Bones Yes 
<5% Ki67 
staining 
22 52 F Phaeo - No 
Lungs, Soft tissue, 
Intraperitoneal, Liver, 
bones 
Yes N/A 
 
  M= Male, F= Female, Para= Paraganglioma, Phaeo= Phaeochromocytoma, N/A= non available, SDH-B= 
Succinate dehydrogenase B 
* Treatment due to incomplete resection (inoperable) / Progression. Bone metastasis developed during 
follow-up. 
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Table 2 Radionuclide and additional treatment to patients with progressive 
Paragangliomas/Phaeochromocytomas. 
Case Treatment 
Treatment 
cycles 
Total 
Number of 
Treatments 
Cumulative 
Activity (MBq) 
Somatostatin 
analogue 
treatment 
Additional Treatment 
1 (131)I-MIBG 1 3 16319 No 
Chemotherapy 
(oxaliplatin capecitabin) 
2 (131)I-MIBG 1 1 3200 No - 
3 
Comb((131)I-
MIBG/(90)Y-
DOTATATE) 
3 8 25644 Yes External Radiotherapy  
4 
(90)Y-
DOTATATE 
1 3 7780 No Chemotherapy (CVD) 
5 (131)I-MIBG 1 3 15436 No - 
6 
(90)Y-
DOTATATE 
1 3 3600 No 
Samarium Nuclide 
Therapy 
7 (131)I-MIBG 1 5 13000 No - 
8 (131)I-MIBG 1 3 22779 No Chemotherapy (CVD) 
9 (131)I-MIBG 1 3 N/A No - 
10 (131)I-MIBG 3 10 66436 No External Radiotherapy 
11 
(177)Lu-
DOTATATE 
1 3 N/A No 
External Radiotherapy, 
Chemotherapy (CVD) 
12 
Comb ((131)I-
MIBG, 
(177)Lu-
DOTATATE) 
2 4 28400 No Extrernal Radiotherapy 
13 (131)I-MIBG 1 3 16201 No 
Extrernal Radiotherapy,  
Chemotherapy  
14 
(90)Y-
DOTATATE 
2 5 14621 Yes - 
15 (131)I-MIBG 1 3 6323 No - 
16 (131)I-MIBG 2 4 14917 Yes 
Metastasectomy, External 
Radiotherapy, 
Chemotherapy (cisplatin) 
17 
(90)Y-
DOTATATE 
1 (3)* 4 5680 (11361) No Metastasectomy 
18 
(90)Y-
DOTATATE 
1 3 9177 No - 
19 (131)I-MIBG 1 3 15592 No Chemotherapy (CVD) 
20 
(90)Y-
DOTATATE 
1 3 9427 Yes -  
21 
(90)Y-
DOTATATE 
2 6 17717 No Radiotherapy 
22 
(90)Y-
DOTATATE 
1 1 7256 No - 
 
N/A: Not Available, CVD: Cisplatin, Vinblastine, Dacarbazine Chemotherapy 
*Patient initially treated for locally advanced symptomatic disease. Second and 3rd single treatment 
cycles were given for symptom palliation and not for progression of disease.  
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Table 3 Therapeutic outcomes in patients with PCCs and PGLs 
 
All patients (131)I-MIBG PRRT 
P value 
(compared to 
(131)I-MIBG) 
(90)Y-
DOTATATE 
P value 
(compared to 
(131)I-MIBG) 
Overall 
Survival 
(months) 
41.2±10.4 60.8±11.1 0.09 65.8±12.2 0.08 
Progression 
Free Survival 
(months) 
20.6±3.4 38.5±9.4 0.10 43.2±10.8 0.04 * 
Event Free 
Survival 
(months) 
22±5 17.9±2.8 0.39 18.9±3 0.54 
Response to 
Treatment 
(Non 
progressive 
disease) 
10/16 
(62.5%) 
13/13 (100%) 0.013 * 
11/11  
(100%) 
0.021*  
* P statistically significant 
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Table 4 Therapeutic outcomes in patients with PGLs  
 
PGL patients 
(131)I-
MIBG 
PRRT 
P value 
(compared to 
(131)I-MIBG) 
(90)Y-
(DOTATOC) 
P value 
(compared to 
(131)I-
MIBG) 
Overall 
Survival 
(months) 
22.8±6.3 60.8±11.1 0.012  * 65.8±12.2 0.011  * 
Progression 
Free Survival 
(months) 
14.4±2.9 38.5±9.4 0.018  * 43.2±10.8 0.007  * 
Event Free 
Survival 
(months) 
9.2±2.9 17.9±2.8 0.042* 18.9±3 0.022  * 
Response to 
Treatment 
(Non 
progressive 
disease) 
4/8  
(50%) 
13/13 (100%) 0.005  * 
11/11 
(100%) 
0.008  * 
* P statistically significant 
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Table 5 Haematological and Renal complication in patients with metastatic paragangliomas and 
phaeochromocytomas. 
 
Case Treatment 
Renal 
toxicity 
Cause of toxicity Haematological Toxicity Cause of toxicity 
1 (131)I-MIBG - N/A Neutropenia (Grade 1) 
Chemotherapy for 
bowel cancer 
2 (131)I-MIBG 
Grade 
not 
available 
Renal obstruction 
from tumor 
Thrombocytopenia  (Grade 1), 
Anaemia  (Grade 3) 
Radionuclide 
treatment 
3 
Comb((131)I-
MIBG/(90)Y-
DOTATATE 
Grade 3 
Radionuclide 
treatment 
Neutropenia (Grade 2), 
Lymphocytopenia (Grade 4) 
Radionuclide 
treatment 
4 
(90)Y-
DOTATATE 
- N/A 
Neutropenia (Grade 3), 
Thrombocytopenia (Grade 4) 
Chemotherapy 
(CVD) 
5 (131)I-MIBG - N/A - N/A 
6 
(90)Y-
DOTATATE 
Grade 1 
Radionuclide 
treatment 
 Anaemia (Grade 2), 
Thrombocytopenia (Grade 3) 
Radionuclide 
treatment, Bone 
marrow tumor 
infiltration  
7 (131)I-MIBG - N/A - N/A 
8 (131)I-MIBG - N/A Leukopenia (Grade 2) 
Chemotherapy 
(CVD) 
9 (131)I-MIBG - N/A - N/A 
10 (131)I-MIBG Grade 1 
Radionuclide 
treatment 
Leukopenia (Grade 2), Anaemia 
(Grade 2) 
Radionuclide 
treatment 
11 
(177)Lu-
DOTATATE 
- N/A Thrombocytopenia (Grade 2)  
Radionuclide 
treatment  
12 
Comb [(131)I-
MIBG, (177)Lu-
DOTATATE] 
Grade 
not 
available 
NSAIDS after  
metastatic fracture 
- N/A 
13 (131)I-MIBG - N/A 
Anaemia (Grade 2), Leukopenia 
(Grade 2)  Thrombocytopenia 
(Grade 2) 
Monosomy 7 
14 
(90)Y-
DOTATATE 
- N/A - N/A 
15 (131)I-MIBG - N/A - N/A 
16 (131)I-MIBG - N/A - N/A 
17 
(90)Y-
DOTATATE 
Grade 2 
Radionuclide 
treatment 
- N/A 
18 
(90)Y-
DOTATATE 
- N/A - N/A 
19 (131)I-MIBG - N/A - N/A 
20 
(90)Y-
DOTATATE 
- N/A - N/A 
21 
(90)Y-
DOTATATE 
- N/A - N/A 
22 
(90)Y-
DOTATATE 
- N/A - N/A 
N/A: Non Applicable 
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